This study states that Respiratory syncytial virus (RSV) is an important cause of respiratory infections, with the most severe infections occurring in young children, older adults, and adults with chronic co-morbidities.1, 2 Acute lower respiratory infections (bronchiolitis and pneumonia) due to RSV are among the most common causes of hospital admission (estimated 3.2 million annually) and hospital deaths (estimated 59 600) in young children globally and are associated with a high hospitalization cost burden.3, 4 The overall number of deaths associated with RSV is less certain but has been estimated to be between 94 600 and 149 400 deaths in young children globally.5 RSV disease in young children has been associated with persisting sequelae such as recurrent wheeze and asthma later in childhood.6 The burden of severe disease and deaths from RSV in high-risk adults remains uncertain but initial estimates suggest that influenza virus is more common than RSV, but RSV infection has a higher risk of death than seasonal influenza in adults.7 The RSV vaccine development landscape is evolving rapidly. There are currently several vaccine candidates and monoclonal antibodies in various stages of clinical trials.8, 9 The World Health Organization (WHO) Product Development for Vaccines Advisory Committee assessed RSV as the most promising new vaccine of potential major public health importance that may be ready for widespread implementation in the next 10 years.

Reference link-